Barinthus Biotherapeutics (BRNS) Change in Account Payables (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has 7 years of Change in Account Payables data on file, last reported at $644000.0 in Q1 2026.

• Quarterly Change in Account Payables rose 155.76% year-over-year to $644000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$403000.0 (down 250.94% YoY) and the FY2025 annual result came in at -$2.2 million, down 345.21% from the prior year.
• Change in Account Payables improved to $644000.0 in Q1 2026, from -$348000.0 in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $2.3 million in Q3 2023 to a low of -$3.8 million in Q4 2023.
• A 5-year average of -$170470.6 and a median of -$348000.0 in 2025 frame the typical range for Change in Account Payables.
• Annual changes were most pronounced in 2022 — Change in Account Payables jumped 975.44% — and 2023, when it plunged 480.26%.
• Tracing BRNS's Change in Account Payables over 5 years: stood at $998000.0 in 2022, then sank by 480.26% to -$3.8 million in 2023, then jumped by 87.88% to -$460000.0 in 2024, then gained by 24.35% to -$348000.0 in 2025, then jumped by 285.06% to $644000.0 in 2026.
• The last three Change in Account Payables figures came in at $644000.0 (Q1 2026), -$348000.0 (Q4 2025), and -$1.0 million (Q3 2025), per Business Quant data.